Background and objectives Malnutrition and/or inflammation may modify the risk relationship of total cholesterol with cardiovascular disease in CKD patients. However, it is unclear whether the relationship of total cholesterol with cardiovascular events and mortality varies by proteinuria. Results During a median 2.8-year follow-up, there were 471 (14.3%) deaths and 545 (16.5%) cardiovascular events. In an adjusted Cox model, the two highest quartiles of total cholesterol (hazard ratio, 1.90; 95% confidence interval, 1.16 to 3.13 and hazard ratio, 2.00; 95% confidence interval, 1.18 to 3.39 versus quartile 1, respectively) were associated with a significant higher risk of all-cause mortality in patients with urine protein-to-creatinine ratio,1 g/g (n=1535), but this higher risk was not seen in those patients with urine protein-to-creatinine ratio$1 g/g (n=1768; hazard ratio, 0.75; 95% confidence interval, 0.53 to 1.07 and hazard ratio, 0.70; 95% confidence interval, 0.49 to 1.02 versus quartile 1, respectively). The interaction between total cholesterol and proteinuria with all-cause mortality was significant (interaction, P=0.05). However, the relationship between total cholesterol and cardiovascular events did not significantly differ by proteinuria (interaction, P=0.91).
Introduction
The health risks caused by lipid abnormalities, including higher total cholesterol and LDL cholesterol and lower HDL cholesterol levels, are well recognized in the general population (1, 2) . Recently, we also reported that dyslipidemia was independently associated with progression to renal replacement therapy and rapid renal progression in moderate to advanced CKD patients (3) . However, the influence of dyslipidemia on mortality is inconclusive in CKD populations, although dyslipidemia has been prevalent in the early stage of CKD (4, 5) . Previous studies reported that higher total cholesterol was associated with a higher risk of mortality in the absence of malnutritioninflammation (M-I), but the mortality risk was lower in the presence of M-I in chronic renal failure (5, 6) . This seemingly paradoxical relationship can be explained by M-I represented by low albumin, low body mass index (BMI), or high C-reactive protein (CRP) (5) (6) (7) .
Proteinuria is a common finding in CKD patients, irrespective of the causes, and virtually almost all CKD patients present with varying degrees of proteinuria (8) . Previous studies have shown that proteinuria may accelerate kidney disease progression, and reduction in proteinuria correlates closely with slowing down renal disease progression (9, 10) . Proteinuria is not just important as a marker of renal disease, but it is also associated with catabolic processes, protein-energy wasting, hypoalbuminemia, and inflammation (11, 12) . Proteinuria could, therefore, serve as a surrogate marker of inflammation. However, it is unclear whether the relationship of total cholesterol with mortality in CKD, particularly when proteinuria is so common, varies by amount of proteinuria (8) .
Recently, the Study of Heart and Renal Protection study showed that simvastatin plus ezetimibe reduced the incidence of major atherosclerotic events in patients with advanced CKD (13) . However, there was no reduction in vascular death. Previous observational study showed that M-I modified the relationship between cholesterol and cardiovascular disease (5, 6) . We, thus, hypothesize that an effect modifier could modify the relationship between cholesterol and mortality. In CKD, both hypoalbuminuria and proteinuria could separately contribute to impaired lipoprotein catabolism and increased oxidative stress (14, 15) . We also propose that the relationship between cholesterol and mortality differs by amount of proteinuria. Therefore, we examined the associations of total cholesterol with all-cause mortality and cardiovascular events and analyzed if these associations differed when different degrees of proteinuria in CKD stages 3-5 patients were considered.
Materials and Methods

Participants and Measurements
Integrated CKD care program Kaohsiung for Delaying Dialysis (ICKD) study was designed as a prospective cohort to investigate the impact of integrated CKD care program on clinical outcomes from a diverse group of CKD stages 1-5 patients. CKD was defined using the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines, and the CKD stage was classified using patients' baseline estimated GFR (eGFR) (16) . The included population was CKD patients not on renal replacement therapy. The exclusion criterion was AKI defined as more than a 50% decrease in eGFR in 3 months. The study recruited patients from the nephrology outpatient departments of two hospitals in southern Taiwan. Between November 11, 2002 and May 31, 2009, 3749 patients received integrated CKD care program and were followed up until July 31, 2010; 90 patients failed to be followed up in less than 3 months, and 356 stages 1-2 CKD patients were excluded. A total of 3303 patients with CKD stages 3-5 was analyzed.
Baseline variables included demographic features (age and sex), medical history (diabetes mellitus [DM], hypertension, and cardiovascular disease), examination findings (BMI and mean arterial pressure), laboratory data (albumin, hemoglobin, total cholesterol, HDL cholesterol, LDL cholesterol, non-HDL cholesterol, total cholesterol/HDL ratio, CRP, glycated hemoglobin [HbA1c], uric acid, total calcium, phosphate, and urine protein-to-creatinine ratio [Upcr]), and medication history (statins, fibrates, angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, and other antihypertension drugs). The demographic features were the baseline record, and the medical history was obtained by reviewing doctors' charts. M-I was defined as lower serum albumin,3.5 mg/dl or CRP.10 mg/L (5). The mean arterial pressure was calculated by the averaged systolic and diastolic BP measured 3 months before and after enrollment. Biochemical examinations were done on the initial visit, the baseline visit (confirming the CKD nature), and then every 3 months as the protocol. The laboratory data from 3 months before baseline visit to 3 months after baseline visit were averaged and analyzed.
Quantification of Renal Function
Kidney function was quantified by using eGFR derived from the simplified Modification of Diet in Renal Disease Study Equation. The equation was eGFR (ml/min per 1.73 m 2 )=1863serum creatinine 21 .154 3age 20.203 30.742 (for women) (17) . We classified our patients with evidence of kidney damage lasting for more than 3 months into CKD stages 3-5 based on eGFR levels of 30-59, 15-29, and ,15 ml/min per 1.73 m 2 , respectively.
Outcomes
Two outcomes were assessed: all-cause mortality and cardiovascular events. Survival status and cause of death were ascertained by review of death certificates using charts or the National Death Index. Cardiovascular events were ascertained by reviewing charts and defined as hospitalization for acute coronary syndrome (Deyo's modified Charlson score; International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM]: 410.x-412.x), acute cerebrovascular disease (ICD-9-CM: 430.x-438.x), congestive heart failure (ICD-9-CM: 428.x), and peripheral arterial occlusion disease (ICD-9-CM: 443.9, 441.x, 785.4, V43.4, and procedure 38.48) and death by aforementioned causes (18) . If the cardiovascular event developed after initiation of dialysis and was not managed in our two hospitals, it was not included in our analysis. The chart reviewers were blinded to the study purposes and proteinuria values. Models for the all-cause mortality included patients who reached renal replacement therapy and were censored only at death or the end of follow-up. Models for cardiovascular events were censored at the development of aforementioned events, death, or the end of follow-up. Time zero was the date of enrollment in the ICKD care program.
Statistical Analyses
Summary statistic results of baseline characteristics of all patients and stratification by Upcr and total cholesterol quartiles were expressed as percentages for categorical data, mean 6 SD for continuous variables with approximately normal distribution, and median and interquartile range for continuous variables with skewed distribution. The differences between groups were checked by chisquared test for categorical variables or independent t test for continuous variables.
Cox proportional hazards analyses were used to investigate the degree of proteinuria as a potential effect modifier for relationships between quartiles of lipid profile with all-cause mortality and cardiovascular events. Quartile 1 was taken as the reference category. Covariates were included into these models if their P value was less than 0.05 in univariate analysis, and skewed distributed continuous variables were log-transformed to attain normal distribution. The adjusted covariates included age, sex, DM, cardiovascular disease, current smoker, BMI, mean arterial pressure, eGFR, log-transformed Upcr, albumin, hemoglobin, log-transformed CRP, HbA1c, uric acid, phosphate, log-transformed triglyceride, statins, fibrates, angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, and other antihypertension drugs use. The Cox model included main effects of the selected variables as well as the interaction effect of cholesterol and proteinuria.
Also, the statistical tools for regression diagnostics, such as verification of proportional hazards assumption and check for multicollinearity, were applied to discover model or data problems. The stratification of variables against proportional hazards assumption was applied. Statistical analysis was performed using the R 2. 
Results
Baseline Characteristics of Study Patients
A total of 3303 nondialyzed CKD patients was included. Their mean age was 63.5613.5 years, and there were 1909 men and 1394 women. The mean eGFR and total cholesterol levels were 24.7615.1 ml/min per 1.73 m 2 and 195.7653.7 mg/dl, respectively; 32.7% of study patients were on statins therapy, and 8.3% of patients were on fibrates at baseline. The underlying etiology of CKD in our patients included 1258 patients with diabetic kidney disease (38.1%), 1168 patients with nondiabetic glomerular diseases (35.4%), 300 patients with tubulointerstitial diseases (9.1%), 368 patients with hypertension (11.1%), and 208 patients with other diseases (6.3%).
The differences between patients with Upcr,1 and $1 g/g are shown in Table 1 . Three Upcr, eGFR, and BP measurements were used in this period. Compared with patients with Upcr,1 g/g, patients with Upcr$1 g/g were found to have higher total cholesterol, have higher non-HDL Table 2 shows the demographic and clinical characteristics stratified by both total cholesterol quartiles and level of proteinuria. The cutoff values of quartiles of total cholesterol were ,162, 162-191, 192-221, and $221 mg/dl, respectively. Patients with lower total cholesterol levels were older, were more likely women, had higher prevalence of cardiovascular disease, had lower mean arterial pressure, had more advanced CKD stages, had lower hemoglobin, and had a lower use of statins in each proteinuria category.
Interaction between Total Cholesterol and Proteinuria with All-Cause Mortality and Cardiovascular Events
There were 471 deaths (14.3%) during a median of 2.8 years of follow-up. Table 3 shows a Cox proportional hazards regression analysis for all-cause mortality. For all patients, in adjusted models, there was no significant correlation between total cholesterol and all-cause mortality.
The association of the adjusted hazard ratio (HR) for mortality with total cholesterol differed significantly between patients with Upcr,1 and $1 g/g (interaction, P=0.05). In the subgroup of Upcr,1 g/g, the highest two quartiles of total cholesterol increased risks for mortality in adjusted models. The adjusted HR for quartile 3 versus quartile 1 was 1.90 (95% confidence interval, 1.16 to 3.13), and the adjusted HR for quartile 4 versus quartile 1 was 2.00 (95% confidence interval, 1.18 to 3.39). The HR for mortality increased as total cholesterol was higher in patients with Upcr,1 g/g, whereas the HR for mortality with total cholesterol was lower in patients with Upcr$1 g/g, although these associations did not reach statistical significance.
There were 545 cardiovascular events (16.5%) during a median of 2.8 years of follow-up. Table 4 shows a Cox proportional hazards regression analysis for cardiovascular events. In adjusted models, the interactions of proteinuria with cardiovascular events were not significant in either all patients or subgroups of patients (interaction, P=0.91). Figure 1 illustrates the adjusted overall survival curves according to quartiles of total cholesterol (Upcr,1 g/g) ( Figure 1A ), total cholesterol (Upcr$1 g/g) ( Figure 1B) , non-HDL cholesterol (Upcr,1 g/g) ( Figure 1C ), non-HDL cholesterol (Upcr$1 g/g) ( Figure 1D ), total cholesterol/HDL ratio (Upcr,1 g/g) ( Figure 1E ), and total cholesterol/HDL ratio (Upcr$1 g/g) ( Figure 1F ). The HR for mortality increased as total cholesterol, non-HDL cholesterol, and total cholesterol/HDL ratio increased in patients with Upcr,1 g/g, whereas the HR decreased in patients with Upcr$1 g/g. Table 3 . Values expressed as hazard ratio (HR) and 95% confidence interval (CI). Adjusted for age, sex, diabetes mellitus, cardiovascular disease, current smoker, body mass index, mean arterial pressure, estimated GFR, log-transformed urine protein-to-creatinine ratio (Upcr), albumin, hemoglobin, log-transformed C-reactive protein, glycated hemoglobin, uric acid, phosphate, logtransformed triglyceride, statins, fibrates, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, and other antihypertension drugs use. We also performed risk association analysis using the CKD Epidemiology Collaboration Study Equation 29 and found similar results (i.e., the HR for mortality increased as total cholesterol increased [1.33, 1.90, and 2.00] in patients with Upcr,1 g/g, whereas the HR for mortality with total cholesterol decreased [0.96, 0.75, and 0.70] in patients with Upcr$1 g/g [interaction, P=0.05]).
Interaction between Other Lipid Profiles and Proteinuria with All-Cause Mortality and Cardiovascular Events
A similar pattern of relationship was observed using non-HDL cholesterol and total cholesterol/HDL ratio as the exposure variable. As shown in Table 3 , the HR for mortality increased as non-HDL cholesterol increased in patients with Upcr,1 g/g, but it decreased in those patients with Upcr$1 g/g (interaction, P=0.05). Similarly, the HR for mortality increased as total cholesterol/HDL ratio increased in patients with Upcr,1 g/g, but it tended to decrease in patients with Upcr$1 g/g (interaction, P,0.01). However, non-HDL cholesterol, total cholesterol/HDL ratio, and their interactions with proteinuria were not associated with cardiovascular events (Table 4) .
Interaction between Total Cholesterol and M-I with All-Cause Mortality and Cardiovascular Events
We also analyzed the interaction of M-I between total cholesterol with mortality and cardiovascular events. The interactions between total cholesterol and M-I with mortality (P=0.16) and cardiovascular events (P=0.12) were not significant. Also, the interactions between other lipid profiles and proteinuria with all-cause mortality and cardiovascular events were not significant. 
Discussion
In the present study, we evaluated the influence of proteinuria on the association of total cholesterol with allcause mortality and cardiovascular events in patients with CKD stages 3-5. We found that the HR for mortality increased as total cholesterol increased in patients with Upcr,1 g/g, whereas the HR for mortality decreased in patients with Upcr$1 g/g, even when total cholesterol increased. A similar pattern of relationship was observed using non-HDL cholesterol and total cholesterol/HDL ratio as the exposure variables.
The American Heart Association guidelines recommended that CKD patients be considered at very high risk for cardiovascular diseases (19) . They exhibit complicated alterations in lipoprotein metabolism, which result in prevalent lipid disorders that are more common than in the general population (1) . The effects might be confounded by nontraditional risk modifiers that were active and innate to the patients. Of those nontraditional factors, nutritional status and inflammation were the most often mentioned (5-7). Liu et al. (6) indicated that, in dialysis patients, higher total cholesterol was associated with a higher risk of mortality in the absence of M-I, but the mortality risk was lower in the presence of M-I. Contreras et al. (5) also Values expressed as hazard ratio (HR) and 95% confidence interval (CI). Adjusted for age, sex, diabetes mellitus, cardiovascular disease, current smoker, body mass index, mean arterial pressure, estimated GFR, log-transformed urine protein-to-creatinine ratio (Upcr), albumin, hemoglobin, log-transformed C-reactive protein, glycated hemoglobin, uric acid, phosphate, logtransformed triglyceride, statins, fibrates, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, and other antihypertension drugs use. Figure 1 . | Adjusted overall survival curves according to quartile of (A) total cholesterol (Upcr<1 g/g), (B) total cholesterol (Upcr ‡1 g/g), (C) non-HDL cholesterol (Upcr<1 g/g), (D) non-HDL cholesterol (Upcr ‡1 g/g), (E) total cholesterol/HDL ratio (Upcr<1 g/g), and (F) total cholesterol/HDL ratio (Upcr ‡1 g/g). The hazard ratio for mortality increased as total cholesterol, non-HDL cholesterol, and total cholesterol/ HDL ratio increased in patients with Upcr,1 g/g, whereas the hazard ratio decreased in patients with Upcr$1 g/g. Upcr, urine protein-tocreatinine ratio.
showed similar results that higher total cholesterol correlated with higher mortality only in CKD patients without significant M-I. Hence, it is possible that other competing factors, such as M-I, might influence patients' outcome imposed by lipid disorder. Our data showed that patients with more severe proteinuria had lower albumin, lower BMI, higher CRP, and more prevalent M-I. Proteinuria has been shown to be associated with catabolic processes, protein-energy wasting, hypoalbuminemia, and inflammation (11, 12) . Therefore, proteinuria can be considered as a surrogate of inflammation as indicated in our study. However, our study did not show that M-I altered the relationship between lipid profile and mortality and cardiovascular events like in previous studies (5, 6) . In these other studies, the patients were African Americans with hypertension, a mean age of 55 years, and an eGFR between 20 and 65 ml/min per 1.73 m 2 (5), and maintenance dialysis patients had a mean age of 57 years (6) . In our study, 35.1% of our study patients were stage 5 CKD patients, and the mean age was 63.5 years; these patients might have had additive risk for morbidity and mortality other than M-I. The relatively advanced CKD stage and older age might explain the inconsistent results with previous studies (5, 6) . Lipid abnormalities in CKD were associated with renal outcomes in CKD patients (4). However, total cholesterol alone might not sufficiently represent the whole scale of lipid disorders in CKD patients (20) . The underlying mechanisms were characterized by increased complex apo-B-containing lipoproteins associated with the defective activities of lipoprotein lipase, hepatic triglyceride lipase, lecithin-cholesterol acyltransferase, and increased triglyceride production (21) . Furthermore, CKD patients exhibited a commonly seen arteriosclerosis derived from calcium/ phosphorus derangement other than atherosclerosis. The above-mentioned difference in either biochemical or structural changes might be important reasons to explain why statins did not show cardiovascular benefits like in non-CKD patients, which was shown in large-scale studies for CKD patients. Another possible explanation was that the insignificant association with cardiovascular events in our study might be related to incomplete ascertainment of cardiovascular events. Also, the difference raised the possibility that the association was not mediated by cardiovascular events.
A systemic review found that nondialysis CKD patients were associated with greater risks for all-cause and cardiovascular mortality than progression to ESRD (22) . The aforementioned study, using eGFR as a measure of CKD, might be limited by the absence of proteinuria measurement. Proteinuria represents a state of dysfunctional glomerular barrier and often precedes clinically recognizable decline of renal function. It is highly prevalent in CKD patients and shows close pathogenic links to worse renal and patient outcomes (9, 23, 24) . Several studies had shown that clinical outcomes might be influenced by different severity of proteinuria (25, 26) . The discrepancy in patients' outcomes in these studies might suggest different mechanisms for risk of ESRD and cardiovascular end points in various populations, but also it emphasizes the importance of proteinuria in differentiating outcome risks among patient stratifications.
There were several limitations in our study. First, the study patients were included from one medical center and one regional hospital in southern Taiwan, and thus, the generalization ability of our results was limited. Second, some variables that might influence outcomes (e.g., the dose or intensity of statin therapy and the status of BP control) were lacking. Third, the cardiovascular event rate was underestimated. Some of our study patients eventually received renal replacement therapy outside of our two hospitals. If the cardiovascular event developed after initiation of dialysis and was not managed in our two hospitals, it was not included in our analysis. The fact that the cardiovascular events could not be completely identified made informative censoring less substantial than expected. Fourth, the possibility of confounding needs to be considered. The test for interaction is not significant in two of the sensitivity analyses for nonstatin users and CKD stages 3-4 (P=0.06 and 0.07, respectively).
In conclusion, our data suggest that the association between cholesterol and mortality varies by level of proteinuria in moderate and advanced stage CKD patients. Future interventional studies are needed to evaluate the significance of cholesterol reduction on the clinical prognosis in CKD patients with different degrees of proteinuria.
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